Endobronchial Cancer - Pipeline Review, H2 2012

Description: Endobronchial Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Endobronchial Cancer - Pipeline Review, H2 2012', provides an overview of the Endobronchial Cancer therapeutic pipeline. This report provides information on the therapeutic development for Endobronchial Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Endobronchial Cancer. 'Endobronchial Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Endobronchial Cancer.
- A review of the Endobronchial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Endobronchial Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Endobronchial Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Endobronchial Cancer pipeline depth and focus of Endobronchial Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Endobronchial Cancer Therapeutic Products under Development, Key Players in Endobronchial Cancer Therapeutics, Endobronchial Cancer Pipeline Overview, Endobronchial Cancer Pipeline, Endobronchial Cancer Pipeline Assessment

Contents:

2
List of Tables 3
List of Figures 3
Introduction 4
REPORT COVERAGE 4
Endobronchial Cancer Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Endobronchial Cancer 6
Endobronchial Cancer Therapeutics under Development by Companies 8
Endobronchial Cancer Therapeutics under Investigation by Universities/Institutes 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Endobronchial Cancer Therapeutics – Products under Development by Companies 11
Endobronchial Cancer Therapeutics – Products under Investigation by Universities/Institutes 12
Companies Involved in Endobronchial Cancer Therapeutics Development 13
Steba Laboratories Ltd. 13
Endobronchial Cancer – Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Drug Profiles 19
Stakel Mediated VTP Therapy - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Cisplatin - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Endobronchial Cancer Therapeutics - Dormant Products 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

List of Tables
Number of Products Under Development for Endobronchial Cancer, H2 2012 6
Products under Development for Endobronchial Cancer – Comparative Analysis, H2 2012 7
Number of Products under Development by Companies, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 9
Comparative Analysis by Mid Clinical Stage Development, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Steba Laboratories Ltd., H2 2012 13
Assessment by Monotherapy Products, H2 2012 14
Assessment by Stage and Route of Administration, H2 2012 16
Assessment by Stage and Molecule Type, H2 2012 18
Endobronchial Cancer Therapeutics – Dormant Products 22

List of Figures
Number of Products under Development for Endobronchial Cancer, H2 2012 6
Products under Development for Endobronchial Cancer – Comparative Analysis, H2 2012 7
Products under Development by Companies, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Mid Clinical Stage Products, H2 2012 10
Assessment by Monotherapy Products, H2 2012 14
Assessment by Route of Administration, H2 2012 15
Assessment by Stage and Route of Administration, H2 2012 16
Assessment by Molecule Type, H2 2012 17
Assessment by Stage and Molecule Type, H2 2012 18

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Endobronchial Cancer - Pipeline Review, H2 2012
Web Address: http://www.researchandmarkets.com/reports/2216806/
Office Code: SCD2FPVB

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Type</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World